A rational approach to evidence gaps in the management of osteoporosis |
| |
Authors: | Rosen Clifford J Brown Sue A |
| |
Institution: | a Maine Center for Osteoporosis Research and Education, St. Joseph Hospital, Bangor, Me b The Jackson Laboratory, Bar Harbor, Me c Division of Endocrinology, Department of Medicine, University of North Carolina-Chapel Hill, Chapel Hill, NC |
| |
Abstract: | Major advancements in the treatment of osteoporosis have occurred over the last decade. Therapies including the anti-resorptive drugs such as alendronate and risedronate have been shown in randomized placebo-controlled trials to increase bone mineral density and reduce fracture risk. Anabolic therapy in the form of parathyroid hormone has been introduced as the first treatment to build bone mass. However, gaps in our knowledge about specific management issues that arise frequently among primary care providers persist. In this paper, three common clinical scenarios are discussed: a postmenopausal woman with only slightly reduced bone mineral density; an osteoporotic woman on anti-resorptive therapy for more than 5 years; and a woman who continues to fracture despite treatment. Evidence gaps in each treatment scenario are presented, and rational approaches to management are suggested. |
| |
Keywords: | Osteoporosis Osteopenia Anti-resorptive Parathyroid hormone |
本文献已被 ScienceDirect PubMed 等数据库收录! |
|